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Abstract
Radioguided surgery using 68-gallium labelled somatostatin analogues is a promising method for detection of small, intra-ab-
dominal, neuroendocrine neoplasm (NEN). However, due to high background activity (physiological uptake in e.g. spleen, 
adrenal glands and kidneys) tumours of the tail and body of pancreas might be impossible to detect with hand-held gamma 
probe. Therefore a new concept of intraoperative PET/CT scan of the resected tissue can be helpful in determining whether 
the tumour has been excised within the margins of healthy tissue.
A 71-year-old woman with primary, non-metastatic NEN of the tail of pancreas is described. The tumour was diagnosed us-
ing MRI and PET/CT scan. Before operation patient was administered intravenously 80 MBq of 68Ga-DOTATATE. The surgery 
procedure was performed 60–180 minutes post injection. During the procedure pancreas was visualized, but the tumour could 
not be localized neither with palpation nor gamma probe. The tail of the pancreas was resected en bloc with spleen and ad-
jacent lymph nodes. PET/CT scan of the tissue specimen was performed immediately followed by pathological examination.
PET/CT scan of the resected tissue showed moderate activity in the tail of pancreas, and a small focus of high activity in the 
tail. Area of high SSTR expression in the tail corresponded with preoperative findings in MRI and whole-body PET/CT. Histo-
pathological examination of the specimen confirmed the presence of neuroendocrine tumour grade 1.
Immediate PET/CT scan of the surgical specimen can bring new quality to intraoperative assessment of completeness of 
resection of neuroendocrine tumours.
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Introduction
Pancreatic neuroendocrine tumours (PNENs) are heterogenic 
subgroup of gastropancreatic neuroendocrine tumours GEP NENs, 
and comprise approximately 10% of all pancreatic tumours [1, 2]. 
Characteristic feature of well differentiated PNENs (G1 and G2 ac-
cording to the WHO classification) is overexpression on their cell 
membrane of somatostatin receptors (SSTR) — mainly subtype 2 
[3, 4]. Overexpression of SSTR2 on PNEN cells enables the applica-
tion of somatostatin-labelled analogues not only in diagnosis and 
therapy, but also in an intra-operative localizing of tumour [5–8].
During surgery, small pancreatic NEN is very difficult to detect 
and remaining tumour tissue leads to unsuccessful treatment. 
Because of such difficulties new, intra-operative techniques are 
essential for real-time primary tumour detection leading to its full 
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excision. Preliminary report has shown that in spite of its draw-
backs (high background activity particularly from kidneys and 
spleen) intraoperative radio-guided surgery (RGS) using a 99mTc 
labelled somatostatin analogue — [99mTc-EDDA/HYNIC] octreotate 
may improve the rate of primary tumours detection and small me-
tastases and increase efficacy of surgical treatment of GEP-NEN [9]. 
Recently for the first time intraoperative gamma probe detection 
using 68Ga labelled somatostatin analogues for a GEP NEN in 9 
patients has been reported by Kaemmerer et al. [8]. Intraoperative 
18FDG PET/CT as a new oncological approach was introduced by 
Hall et al. [3].
Case report
A 71-year-old female with diabetes type II, hypertension, psoria-
sis and chronic kidney disease (stage 1) was admitted in May 2012 
to the Department of Rheumatology, with the six-month history of 
myalgia, particularly in the shoulder and pelvic girdle, associated 
with arthralgia and chronic fatigue.
Laboratory tests showed 4–5 fold increase of plasma creatine 
kinase (CK). Rheumatoid factor (RF) and CRP were normal. 
The blood sample was taken for diagnosis of other causes of 
myopathy.
It was considered highly likely that this patient’s weakness, 
myalgia and elevated CPK occurred as part of a paraneoplas-
tic syndrome, despite patient’s good general condition and 
lack of obvious symptoms that might help localize a potential 
site of disease. As a next step of diagnostic evaluation chest 
X-Ray, abdominal ultrasound, chest, abdomen and pelvis MR 
were performed. An abdominal MR scan showed a large ir-
regular focal mass in the head of the pancreas measuring 
26 × 38 × 47 mm, hyperintense on T1- and T2-weighted 
images (Figure 1). The mass was isointense with the intraab-
dominal and subcutaneous fat on both T1- and T2-weighted 
images and was found to be homogenously suppressed on 
frequency selected fat-suppression images. There was no 
contrast enhancement after the use of gadolinium-DTPA. 
In the tail of the pancreas MR demonstrated a small lesion 
9 mm in diameter, enhancing in both the arterial and portal 
venous phases — with typical appearance of pancreatic NEN. 
Contrast enhanced MR imaging of the pancreas confirmed 
the suspicion of NEN tumour in the tail (Figure 2). The patient 
was immediately referred to the Department of Surgery (Warsaw 
Medical University Hospital) for further diagnostic evaluation 
in order to establish the optimal management. Before surgi-
cal treatment patient underwent whole body PET/CT imaging 
(Siemens Biograph 64) using 68Ga DOTATATE in July 2012. The 
PET/CT imaging demonstrated increased uptake in the tail of 
the pancreas (SUVmax 16.2; physiological SUVmax < 9.2 [10]) 
corresponding to the hyperattenuated tumour seen on CT (Fig-
ure 3). There was no uptake of the radiotracer in the head of 
pancreas. Other sites of disease have been ruled out. Cancer 
plasma markers: CA 19–9 (4.09 U/ml), CgA (88 µg/l) showed 
proper values. Based on the confirmation of the presence of 
overexpressed SSTR on the tumour cells — characteristic fea-
ture of well-differentiated NEN — distal pancreatectomy with 
en bloc splenectomy was planned. Due to the high density of 
SSTR2 on pancreatic NEN cells, we hypothesized that it is fea-
sible to utilize intraoperative RGS and ex vivo specimen PET/CT 
imaging. Therefore, for the first time the new approach of intra-
operative handheld gamma probe detection accompanied by 
specimen PET/CT imaging using preoperative 68Ga-DOTATATE 
injection was used for neuroendocrine tumour localization and 
verification of resection completeness in our patient.
On the day of surgery, a dose of 80 MBq 68Ga-DOTATATE 
was injected iv approximately 60 minutes before the surgical 
exploration. On opening the abdominal cavity there was no mac-
roscopic signs of neoplasmatic dissemination. Intraoperatively, 
a handheld gamma probe (Neoprobe 2000 series) was used to 
assess the localization of the site of increased 68Ga-DOTATATE 
uptake within the tail of the pancreas. Identification of tumour 
was hindered by high background activity. RGS technique in the 
presented case did not allow identification of primary tumour 
in the pancreas. Lesion was not palpable and non-visible by 
surgeon. The patient subsequently underwent distal pancrea-
tectomy en bloc with splenectomy. The resected specimens un-
Figure 1. MR scan showed a large irregular mass in the head of the 
pancreas hypointense on fat-suppressed T1-weighted images
Figure 2. Contrast enhanced MR imaging of the pancreas confirmed 
the suspicion of NEN tumour in the tail




derwent imaging with PET/CT scanner at 200 minutes after 
the 68Ga-DOTATATE injection. PET/CT (6 min/bed) imaging 
revealed the presence of increased radiotracer uptake in the 
tail of pancreas, corresponding to the site previously seen on 
the preoperative diagnostic whole body 68Ga-DOTATATE PET/CT 
and confirmed completeness of surgical resection (Figure 4). 
The specimens were sent to Department of Pathology for stand-
ard pathologic evaluation. Histopathological examination con-
firmed the diagnosis of neuroendocrine tumours G 1 (Figure 5). 
Lymph nodes were negative and surgical margins were clear 
of tumour tissue. The postoperative course was complicated 
by pancreatic leak. Nevertheless the patient was discharged 
in good condition.
Discussion
Pancreatic NEN comprise a heterogeneous group of neo-
plasms for which treatment is variable, depending on the size, 
localization in the pancreas, clinical stage (TNM), differentiation 
grade (histological grading system), functional status (func-
tional or non-functional) as well as other factors. In case of 
localized PNEN complete resection (R0) of the tumour is suf-
ficient to cure the disease but it is essential to confirm negative 
margins both intraoperatively and on final pathology. Localized 
well differentiated PNENs may be removed with organ preserv-
ing techniques like: enucleation or distal pancreatectomy. The 
main concern in the organ sparing surgery is the difficulty of 
Figure 5. Histopathological examination confirmed the diagnosis of neuroendocrine tumours G 1. A. Well-differentiated neuroendocrine pancreatic 
tumour — pseudoglandular and trabecular growth pattern (H & E stain, magnification 100 ×); Immunostaining showing strong and diffuse 
expression of chromogranin A (B) and synaptophysin (C) in tumour cells (magnification 100 ×); D. A low cell-proliferative index — Ki67 < 2% 
(magnification 100 ×) 
Figure 4. PET/CT with 68Ga-DOTATATE of resected specimens revealed the presence of increased radiotracer uptake in the tail of pancreas, 
corresponding to the site previously seen on the preoperative diagnostic whole body 68Ga-DOTATATE PET/CT and confirmed completeness of 
surgical resection. A. Fusion PET/CT; B. PET; C. MIP
Figure 3. PET/CT with 68Ga DOTATATE demonstrated increased uptake in the tail of the pancreas (SUVmax 16.2) with normal uptake in the head of 
pancreas. A. Fusion PET/CT; B. PET; C. CT
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precise intraoperative tumour localization, margin tumour de-
lineation and real-time verification of complete resection with 
the possibility of missing small- and nonpalpable tumours. 
Because of such difficulty new intraoperative techniques have 
been under clinical research including intraoperative US and 
RGS using labelled somatostatin analogues. Recently the 
preliminary data [8] shown that intra-operative RGS using gal-
lium-68-labeled somatostatin receptor analogues is a promising 
method for real-time detection of small pancreas NET and for 
assessing surgical margins by detecting presence of tumour 
ex vivo within the resected tissue. The successful use of RGS 
in PNEN patients is a function of radiopharmaceutical uptake 
by tumour cells, biodistribution and its clearance kinetics, 
anatomical sites of disease and gamma probe engineering. 
All this multiple factors have been determining the tumour to 
non-tumour (T/NT) ratio and detection threshold. Due to the 
high photon energy of 68Ga isotope and physiological uptake 
from liver, kidney and spleen, achieving diagnostic T/NT ratio 
intraoperatively in upper abdomen may be difficult and poten-
tially complicate tumour detection efficiency.
Therefore to improve precise tumour localization and 
verify completeness of resection we combined RGS with ex 
vivo PET/CT imaging of resected tissue by using preoperative 
68Ga-DOTATATE injection. This innovative approach is based 
on expression of SSTR2 on cells tumours — so analysis of dia-
gnostic preoperative SRS PET/CT imaging had a crucial effect 
on selecting proper patient for this modality. A semiquantita-
tive parameter SUVmax derived from 68Ga-DOTATATE PET/CT 
as an indirect method for receptor density mapping. In our 
patient SSTR2 expression was relatively high (SUVmax 16.2) 
but localization of tumour near the hilum of the spleen seriously 
hampered the gamma-probe detection. Knowledge of the normal 
68Ga-DOTATATE distribution is very important for understanding 
RGS limitations and possible pitfalls in intraoperative localization 
of pancreatic NET. The normal distribution of 68Ga-DOTATATE 
was described by Kunikowska et al. [10]. Using semiquantitative 
analysis the highest physiological uptake of 68Ga-DOTATATE in 
the abdomen was seen in the spleen, [SUVmax, 18.9 (6.6)] due 
to high expression SSTR2. The kidney showed a high uptake 
in the cortex and the urinary tract with SUVmax 14.2 (3.6) [10]. 
Keeping these in mind, it is very probable that NET in the tail 
of the pancreas with lower or near the same density of SSTR2 
as in spleen may not be detected with RGS — like in our pre-
sented case.
To provide verification of resection completeness, we per-
formed ex vivo PET/CT imaging of resected tissue immediately 
after surgical excision. PET/CT scan of the resected tissue re-
vealed increasing isotope uptake lesion in the resected tail 
of the pancreas corresponding with preoperative findings in 
preoperative PET/CT and MR with good safety margin excision. 
Immunohistochemistry and histopathology of the resected tissue 
confirmed complete tumour resection with adequate surgical 
margin. The new approach presented here — ex vivo PET/CT 
imaging of resected tissue — seems to be very promising for 
ex vivo intraoperative localization and verification of oncological 
safety margin excision. However, it should be mentioned that 
surgical techniques like enucleation, exclude PET/CT as trustful 
evaluation method.
In case of unsuccessful gamma probe detection of tumour 
localization, other diagnostic tools may be very helpful. Ac-
cording to literature IOUS [4] can be used to detect tumour 
localization and enables the surgeons to perform more precise 
tumour excision with good safety margin and without injury 
to the main pancreatic duct. In case of small, non-palpable 
PNEN, intraoperative localization remains always difficult and all 
this methods combined may provide to more effectiveness sur-
gical treatment.
The main limitation of presented approach is the 68 minute 
half-life of 68Ga isotope. This is relevant both to intraoperative 
gamma probe detection and specimen PET/CT imaging. By in-
creasing the scan time (6 minutes for acquisition), we have been 
able to generate high quality images on the specimen PET/CT 
200 minutes post-injection of the 80 MBq 68Ga-DOTATATE. The 
further studies are necessary with regard to the optimal dose and 
the optimal time of injection prior to the operation. It is also very 
important to find all factors affecting the uptake of 68Ga labelled 
somatostatin analogues therefore resulting in the change of T/NT 
ratio and quality images on ex vivo specimen PET/CT. Factors that 
may affect outcome of intraoperative 68Ga diagnosis are enlisted 
in Table 1.
Table 1. Factors to be taken into account when using 68Ga-DOTATATE in RGS and intraoperative PET/CT scan
Factor Applies to RGS  
or intraoperative  
PET/CT
Remarks
SSTR expression Both Essential for radionuclide imaging/diagnosis, depends on tumour biology and 
affects radiopharmaceutical affinity
68Ga half-life Both Implies constant background updating in RGS, T/NT ratio and elongating acquisition time in PET/CT
Tumour size Both RGS can be a sensitive method, regardless of the size of the tumour. IOUS to be considered 
in selected cases. Optimal CT slice thickness (within postoperative PET/CT procedure) to be 
evaluated
Background issues RGS Updating of background setting, T/NT in vivo and ex vivo evaluation. Site of the disease
Surgical technique PET/CT When the tumour is e.g. enucleated, PET/CT is not trustworthy in evaluating completeness of 
resection due to the absence of adjacent tissue
Gamma-probe engineering RGS Proper collimator, energy window setting etc.




This case report may give a special attention to change 
the strategy of surgical management of localized, small, well 
differentiated PNEN to provide long term cure to the patient 
and prevent recurrence. Basing on our experience in surgical 
management in case of localized well differentiated PNET we 
strongly recommend combined modality approach: RGS with 
IOUS and ex vivo PET/CT imaging of resected tissue, however 
further studies are needed.
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